Loading stock data…
Guardant Health, Inc. (GH)
$160.98-0.43 (-0.27%)
Market ClosedLast close Sep 8
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Guardant Health, Inc. in the Healthcare sector is trading at $160.98 with a market capitalization of $22.6B. Wall Street consensus targets $194.29 (24 analysts), implying a +20.7% move over the next 12 months. The stock is currently near its 52-week high of $176.58, remaining 36.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +20.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $334.98M↑ | $301.67M↑ | $281.27M↑ | $265.20M↑ | $232.09M |
| Gross Profit | $219.03M↑ | $196.75M↑ | $181.77M↑ | $171.61M↑ | $150.88M |
| Operating Income | -$129.12M↓ | -$121.35M↓ | -$120.81M↓ | -$98.99M↑ | -$106.41M |
| Net Income | -$120.14M↓ | -$112.08M↑ | -$128.49M↓ | -$92.72M↑ | -$99.90M |
Peer Comparison
JNJUNHPFE
Fundamentals
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liqu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.61B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
203.46%
Volume
Today's trading volume
2.04M
Recent News
1 Growth Stock to Add to Your Roster and 2 We Turn Down
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
What Makes Guardant Health (GH) a Compelling Bet?
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]
Guardant Health Faces a $245 Million Patent Judgment, But Its Newer Tests Could Offer Protection
Guardant Health, Inc. (NASDAQ:GH) faces a costly legal setback after a US court ordered the cancer-testing company to pay more than $245.2 million in a DNA-sequencing patent dispute. The final judgment upheld a 2023 jury verdict finding that Guardant willfully infringed two DNA-sequencing patents asserted by TwinStrand Biosciences and the University of Washington. The financial […]
Guardant Health (GH) Stock Could Trade At A 21% Discount Despite Patent Appeal
Guardant Health stock has delivered very strong gains over the past three years, yet its valuation signals are split, with the intrinsic value estimate pointing to upside while broader checks suggest the shares are not a clear bargain. After a recent legal setback and a sharp multi year rise, investors are weighing how much of Guardant Health’s growth potential is already reflected in the current price. Guardant Health has returned about 327.6% over the past three years, which puts more...
Did a US$245 Million Patent Ruling Just Shift Guardant Health's (GH) Investment Narrative?
In August 2026, a U.S. district court entered final judgment that Guardant Health infringed TwinStrand Biosciences and University of Washington DNA sequencing patents, ordering more than US$245.2 million in damages, accrued royalties and interest plus ongoing royalties on 11 products through March 2033. Guardant has said it will appeal and highlighted that updated versions of key tests, including Guardant Reveal and Shield, are excluded from the royalty order, while it continues to challenge...